Joshua Grill, PhD, Director, Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program, UCLA, discusses new therapies for Alzheimer’s Disease. The FDA has currently approved 5 symptomatic therapies…
Joseph Demer, MD, Professor of Opthalmology and Neurology, UCLA David Geffen School of Medicine, discusses double vision, which is not uncommon in the elderly and is traditionally attributed…
Ian A Cook, MD, Director of Unipolar Depression Research, UCLA David Geffen School of Medicine, discusses the use of measurement – based care for depressed patients, which can…
Andrew Charles, MD, Professor, Director of Headache Research and Treatment Program, UCLA David Geffen School of Medicine, discusses migraine as a problem of brain excitability and chemistry rather…
NEW YORK (Reuters Health) – The pure class III anti-arrhythmic drug nifekalant is more effective than lidocaine for terminating refractory ventricular fibrillation (VF) or ventricular tachycardia (VT), Japanese…
NEW YORK (Reuters Health) – Treating septic shock with steroids produces hyperglycemia, but patients are no better off with intensive insulin therapy than with conventional glucose control, according…
NEW YORK (Reuters Health) – In patients with middle cerebral artery occlusion, an alteplase dosage of 0.6 mg/kg IV is comparable to a 0.9 mg/kg dosage for achieving…
NEW YORK (Reuters Health) – Operative mortality after coronary artery bypass grafting (CABG) is higher in women, even after adjustment for preoperative risk factors, according to a study…
NEW YORK (Reuters Health) – It makes no difference whether internal tocodynamometry or external monitoring is used during induced or augmented labor – either way, the rate of…
NEW YORK (Reuters Health) – When paroxysmal atrial fibrillation has not responded to at least one antiarrhythmic agent, radiofrequency catheter ablation is more effective at preventing further episodes…
NEW YORK (Reuters Health) – Prompt treatment of subclinical and clinical seizures in newborns with hypoxic-ischemic encephalopathy (HIE) can potentially decrease brain injury, according to a prospective trial…
NEW YORK (Reuters Health) – High-dose atorvastatin does not protect against contrast-induced nephropathy (CIN) in patients with kidney disease, Italian researchers report. “Statins have recently been proposed for…
